Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors

Ryohei Kuwatsuru, Masumi Kadoya, Akihiro Tanimoto, Shinji Hirohashi, Hitoshi Katayama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A clinical early phase II trial of Gd-BOPTA (E7155) was performed to assess its safety and usefulness for the detection of the hepatic lesions. Seventy-nine patients were assigned to three groups ; a low dose group (0.025 mmol/kg), medium dose group (0.05 mmol/kg) and high dose group (0.1 mmol/kg). In terms of safety, Gd-BOPTA was assessed as "safe" in 76 patients and "somewhat questionable" in three patients including one with nausea and two with obvious changes in laboratory findings. No severe adverse reaction was experienced. In terms of the usefulness of dynamic study, the percentage of more than "useful" in the high dose group, medium dose group and low dose group were 100%, 100% and 76.9%. respectively. The result of "usefulness" of early and delayed post-contrast images showed more than "useful" in over 60% of cases. These results indicated that both dynamic and post-contrast early and delayed images were useful for the evaluation of liver tumors, suggesting that this contrast agent would have characteristics of both extracellular and liver-specific contrast agents.

Original languageEnglish
Pages (from-to)555-563
Number of pages9
JournalNippon Acta Radiologica
Volume56
Issue number8
Publication statusPublished - 1996 Jul

Fingerprint

Contrast Media
Liver
Safety
Neoplasms
Phase II Clinical Trials
Nausea
gadobenic acid

Keywords

  • Contrast media
  • Gd-BOPTA
  • Liver
  • MRI

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kuwatsuru, R., Kadoya, M., Tanimoto, A., Hirohashi, S., & Katayama, H. (1996). Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors. Nippon Acta Radiologica, 56(8), 555-563.

Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors. / Kuwatsuru, Ryohei; Kadoya, Masumi; Tanimoto, Akihiro; Hirohashi, Shinji; Katayama, Hitoshi.

In: Nippon Acta Radiologica, Vol. 56, No. 8, 07.1996, p. 555-563.

Research output: Contribution to journalArticle

Kuwatsuru, R, Kadoya, M, Tanimoto, A, Hirohashi, S & Katayama, H 1996, 'Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors', Nippon Acta Radiologica, vol. 56, no. 8, pp. 555-563.
Kuwatsuru R, Kadoya M, Tanimoto A, Hirohashi S, Katayama H. Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors. Nippon Acta Radiologica. 1996 Jul;56(8):555-563.
Kuwatsuru, Ryohei ; Kadoya, Masumi ; Tanimoto, Akihiro ; Hirohashi, Shinji ; Katayama, Hitoshi. / Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors. In: Nippon Acta Radiologica. 1996 ; Vol. 56, No. 8. pp. 555-563.
@article{07f81fa0a4144872b63741e8d838f8cf,
title = "Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors",
abstract = "A clinical early phase II trial of Gd-BOPTA (E7155) was performed to assess its safety and usefulness for the detection of the hepatic lesions. Seventy-nine patients were assigned to three groups ; a low dose group (0.025 mmol/kg), medium dose group (0.05 mmol/kg) and high dose group (0.1 mmol/kg). In terms of safety, Gd-BOPTA was assessed as {"}safe{"} in 76 patients and {"}somewhat questionable{"} in three patients including one with nausea and two with obvious changes in laboratory findings. No severe adverse reaction was experienced. In terms of the usefulness of dynamic study, the percentage of more than {"}useful{"} in the high dose group, medium dose group and low dose group were 100{\%}, 100{\%} and 76.9{\%}. respectively. The result of {"}usefulness{"} of early and delayed post-contrast images showed more than {"}useful{"} in over 60{\%} of cases. These results indicated that both dynamic and post-contrast early and delayed images were useful for the evaluation of liver tumors, suggesting that this contrast agent would have characteristics of both extracellular and liver-specific contrast agents.",
keywords = "Contrast media, Gd-BOPTA, Liver, MRI",
author = "Ryohei Kuwatsuru and Masumi Kadoya and Akihiro Tanimoto and Shinji Hirohashi and Hitoshi Katayama",
year = "1996",
month = "7",
language = "English",
volume = "56",
pages = "555--563",
journal = "Nippon Acta Radiologica",
issn = "0048-0428",
publisher = "Japan Radiological Society",
number = "8",

}

TY - JOUR

T1 - Early Phase II Trial of Gd-BOPTA (E7155) for the MR Imaging of Liver Tumors

AU - Kuwatsuru, Ryohei

AU - Kadoya, Masumi

AU - Tanimoto, Akihiro

AU - Hirohashi, Shinji

AU - Katayama, Hitoshi

PY - 1996/7

Y1 - 1996/7

N2 - A clinical early phase II trial of Gd-BOPTA (E7155) was performed to assess its safety and usefulness for the detection of the hepatic lesions. Seventy-nine patients were assigned to three groups ; a low dose group (0.025 mmol/kg), medium dose group (0.05 mmol/kg) and high dose group (0.1 mmol/kg). In terms of safety, Gd-BOPTA was assessed as "safe" in 76 patients and "somewhat questionable" in three patients including one with nausea and two with obvious changes in laboratory findings. No severe adverse reaction was experienced. In terms of the usefulness of dynamic study, the percentage of more than "useful" in the high dose group, medium dose group and low dose group were 100%, 100% and 76.9%. respectively. The result of "usefulness" of early and delayed post-contrast images showed more than "useful" in over 60% of cases. These results indicated that both dynamic and post-contrast early and delayed images were useful for the evaluation of liver tumors, suggesting that this contrast agent would have characteristics of both extracellular and liver-specific contrast agents.

AB - A clinical early phase II trial of Gd-BOPTA (E7155) was performed to assess its safety and usefulness for the detection of the hepatic lesions. Seventy-nine patients were assigned to three groups ; a low dose group (0.025 mmol/kg), medium dose group (0.05 mmol/kg) and high dose group (0.1 mmol/kg). In terms of safety, Gd-BOPTA was assessed as "safe" in 76 patients and "somewhat questionable" in three patients including one with nausea and two with obvious changes in laboratory findings. No severe adverse reaction was experienced. In terms of the usefulness of dynamic study, the percentage of more than "useful" in the high dose group, medium dose group and low dose group were 100%, 100% and 76.9%. respectively. The result of "usefulness" of early and delayed post-contrast images showed more than "useful" in over 60% of cases. These results indicated that both dynamic and post-contrast early and delayed images were useful for the evaluation of liver tumors, suggesting that this contrast agent would have characteristics of both extracellular and liver-specific contrast agents.

KW - Contrast media

KW - Gd-BOPTA

KW - Liver

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=0030187749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030187749&partnerID=8YFLogxK

M3 - Article

C2 - 8797346

AN - SCOPUS:0030187749

VL - 56

SP - 555

EP - 563

JO - Nippon Acta Radiologica

JF - Nippon Acta Radiologica

SN - 0048-0428

IS - 8

ER -